ELVN
Enliven Therapeutics, Inc.
Healthcare · Biotechnology · NMS
$41.41
Close 2026-05-28
✗ NOT SCREENED

UNKNOWN MOAT
MODERATE
Data Confidence: 71%
Some financial metrics pending
Market Cap
$2.5B
Trailing P/E
Forward P/E
-17.37
Rev Growth
Profit Margin
0.0%
ROE
-26.6%
Analyst Target
$57.50
Recommendation
STRONG BUY
About Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Ethical Screen
Business ActivityPASS
Debt RatioN/A
Cash RatioN/A
Receivables RatioN/A
Revenue RatioN/A
OverallINSUFFICIENT DATA
Score Ethical: 50.0
Score Valuation: 33.0
Score Quality: 21.2
Score Combined: 30.2

Full Analysis

Opportunity scores, earnings history, insider transactions, institutional holders, analyst consensus, and more.

Unlock with Membership
Opportunity Scores
Valuation50.0
Quality12.5
Cash Flow0.0
Moat40.0
Balance Sheet100.0
Debt Purity50.0
Liquid Purity50.0
Rev Purity50.0
Compliance100.0
Tier: BRONZE · Score: 40.2 · Rank: #4224
Insider Transactions
No insider transaction data.
Top Institutional Holders
No institutional holder data.
Additional Fundamentals
Enterprise Value
$2.0B
Price/Book
5.46
Beta
0.454
Analysts
8
Total Debt
$302.0K
Short Ratio
7.12
Short % Float
0.1%
Employees
61

Elite Intelligence

Trade Consideration with position sizing, convergence signals, and risk analysis. Available to Elite members.

Upgrade to Elite
Trade Consideration
The Opportunity
Score 30.2 (P14 — top 86.3% of scored tickers). Unknown Moat. Ethical FAIL. 8 analysts at None.
Price: $41.41 | Target: $57.00 (+38%)
Score
30
Moat
Unknown
Conviction
Standard
Upside
+38%
The Fundamentals
Profit Margin0.0%
ROE-26.6%
Forward P/E-17.4
Market Cap$2.5B
Position Sizing Scenarios
Stop: $35.20 (-15%) | Entry: $41.41
SharesCostProfit to TargetR:R
To Consensus ($57.00, 8 analysts)
10$414.10+$155.90 (38%)2.5R
50$2,070.50+$779.50 (38%)2.5R
100$4,141.00+$1,559.00 (38%)2.5R
Risk Factors
  • Elevated short interest (7.12 days to cover)
The Verdict
Enliven Therapeutics, Inc. holds a unknown competitive moat.
Quantitative Grade

A single score combining all analytical layers below. A is strongest, D is weakest.

C
Quant Score
45.8
Risk Grade
Layers
7
Quality: HMM_CRISIS
Risk Profile

How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.

VaR 95%
-5.9%
worst expected daily loss, 19 in 20 days
CVaR 95%
-8.1%
avg loss on the worst 5% of days
Annual Volatility
Sortino Ratio
0.86
above 1.0 is good
Max Drawdown
-49.5%
Worst Day
Forward Outlook

Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.

30d Prob Up
90d Prob Up
Median Return 30d
Liquidity Score
75
Liquidity Grade
LIQUID
Trend & Momentum

What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?

Kalman Trend
Trend Strength
Momentum Signal
HMM Regime
RSI Signal
Technical Signals

Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.

MA Crossover
ABOVE_200
Bollinger Position
LOWER_HALF
Beta
Relative Volume
0.5x
Short Interest
Financial Health

Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.

Altman Z-Score
below 1.81 = distress zone
Piotroski F-Score
Earnings Beat Rate
Earnings Consistency
Correlations

These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.

Most Correlated
TickerCorrelation
APGE0.402
IWM0.383
XNCR0.381
CLDX0.372
NRIX0.364
Inverse Correlated
TickerCorrelation
ABC.BH-0.164
CME-0.139
ABF.L-0.126
CBOE-0.125
ABQK.QA-0.116
Seasonality

Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.

Best Day
Thursday
Worst Day
Monday
Best Month
Jan
Worst Month
Dec
Fri-Mon Effect
0.5198768539726096
Momentum Rankings

How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.

1M Return
-5.4%
3M Return
+37.2%
6M Return
+86.7%
12M Return
+154.2%
Momentum Rank
#366
Momentum Signal
STRONG_UP

Get our daily market read free. Join thousands of traders.

Free Explorer Access